Explore the Parkinson’s research intelligence diagram before entering the Neurocompute platform.
AI-driven Parkinson’s research intelligence platform exploring emerging signals, forgotten papers, and therapeutic patterns across the biomedical literature universe.
Not AI summarized yet.
Pending deeper interpretation.
Not AI summarized yet.
Pending deeper interpretation.
Not AI summarized yet.
Pending deeper interpretation.
Not AI summarized yet.
Pending deeper interpretation.
Not AI summarized yet.
Pending deeper interpretation.
Not AI summarized yet.
Pending deeper interpretation.
Review synthesizing spermidine's mechanisms, preclinical neuroprotective data, and clinical perspectives in the aging brain, highlighting autophagy induction, mitochondrial support, and anti-inflammatory effects.
Spermidine engages pathways (autophagy, mitochondrial health, inflammation) directly relevant to alpha-synuclein clearance and neurodegeneration and represents a repurposable, translational candidate for Parkinson's-focused interventions.
Review comparing LRRK2- and GBA1-associated Lewy body disease neuropathology and proposing these genetic subtypes occupy opposite ends of a pathogenic spectrum.
By contrasting LRRK2-linked kinase-related mechanisms with GBA1-driven lysosomal dysfunction, the paper highlights actionable, genotype-driven targets and stratification strategies relevant to therapeutic development and biomarker-driven trials.
A review of pharmacological modulation of the CXCL12 chemokine axis (CXCR4/ACKR3) in brain disorders, describing receptor signaling, pathophysiological roles, and available modulators.
The CXCL12/CXCR4/ACKR3 axis links to neuroinflammation, neuroprotection, BBB integrity and has existing drugs (e.g., CXCR4 antagonists) that could be repurposed for Parkinson's-related neuroinflammatory or neuroprotective strategies, but the paper appears to be a broad review with no PD-specific…
This methods-focused study evaluates Q.Clear PET image reconstruction to shorten scan time for 11C-CFT brain PET/MR imaging, a dopamine transporter (DAT) radioligand used in Parkinsonian biomarker imaging.
Improving scan speed and image quality for DAT PET could enhance clinical throughput, patient tolerance, and feasibility of longitudinal or larger biomarker studies relevant to Parkinson's diagnosis and trial enrollment, but it provides limited direct therapeutic discovery insights.
Computational molecular dynamics study modeling interactions between the ER stress kinase PERK and engineered alpha‑lactalbumin peptides.
Peripheral relevance to Parkinson's because PERK/ER stress is implicated in PD, but the lack of an abstract, absence of alpha‑synuclein, mitochondrial, lysosomal or in vivo data, and no clear translational path make this low priority for therapeutic discovery.
Systematic review of machine‑learning methods applied to remote monitoring for predicting disease outcomes, focused on methodological performance rather than biological mechanisms.
Improving remote monitoring and ML-derived digital biomarkers can help Parkinson’s trial design and outcome measurement but the paper offers limited direct insight for therapeutic targets or mechanistic discovery.
A brief regulatory/clinical note reporting newly issued warnings for carbidopa/levodopa products, with no new mechanistic or preclinical data provided.
Relevant for clinical management and patient safety in Parkinson's disease but offers minimal actionable insight for therapeutic discovery, mechanisms, or biomarker development.
A single-case report describing onset of dyskinesia-hyperpyrexia syndrome after subthalamic nucleus deep brain stimulation for Parkinsonism.
Clinically useful for recognizing and managing a rare DBS complication, but offers limited mechanistic insight or direct therapeutic targets for Parkinson's disease drug discovery.
Based on the title (no abstract provided), the paper appears to describe a multiple-attention deep multimodal fusion network for diagnosing glaucoma and neurodegenerative diseases.
Low direct value for Parkinson's therapeutic discovery—may help in diagnostic/biomarker detection but lacks mechanistic, intervention, or translational therapeutic insights relevant to PD.
Likely an opinion/review arguing that traditional clinical semiology is being supplanted by prodromal/neurobiological approaches to neurology, but provides little direct experimental data or actionable therapeutic mechanisms.
Highlights the importance of identifying prodromal signs and biomarkers relevant to early Parkinson's detection and trial enrollment, but the missing abstract and probable conceptual focus limit immediate translational or drug-discovery utility.
Case report describing paroxysmal dyspnea in a patient with multiple system atrophy attributed to a severe floppy arytenoid causing intermittent airway obstruction.
Minimal value for Parkinson's therapeutic discovery—offers a clinical caution about respiratory complications in atypical parkinsonism but lacks mechanistic insights, biomarkers, or actionable therapeutic leads relevant to PD drug development.
Not AI summarized yet.
Pending deeper interpretation.
Not AI summarized yet.
Pending deeper interpretation.
Not AI summarized yet.
Pending deeper interpretation.
Not AI summarized yet.
Pending deeper interpretation.
Not AI summarized yet.
Pending deeper interpretation.
Not AI summarized yet.
Pending deeper interpretation.
Not AI summarized yet.
Pending deeper interpretation.
Not AI summarized yet.
Pending deeper interpretation.
